We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock
OMIC

Delisted

OMIC was delisted on the 20th of February, 2025.

Back to rankings

69 hedge funds and large institutions have $259M invested in Singular Genomics Systems, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 10

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

11% more funds holding

Funds holding: 62 → 69 (+7)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

43% less capital invested

Capital invested by funds: $450M → $259M (-$191M)

Holders
69
Holders Change
+7
Holders Change %
+11.29%
% of All Funds
1.09%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
17
Increased
34
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$34.4M
2
BlackRock
BlackRock
New York
+$13.1M
3
TM
Tikvah Management
North Carolina
+$5.46M
4
Citadel Advisors
Citadel Advisors
Florida
+$3M
5
PA
Perceptive Advisors
New York
+$2.48M

Top Sellers

Rank Fund Capital Flow
1
RCM
Revelation Capital Management
California
-$23.1M
2
DM
Deerfield Management
New York
-$19.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.68M
4
JP Morgan Chase
JP Morgan Chase
New York
-$4.97M
5
TM
Triatomic Management
California
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
26
Victory Capital Management
Texas
$966K -$36.8K -159 -3%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$895K +$669K +2,893 +157%
Charles Schwab
28
Charles Schwab
California
$693K +$605K +2,614 +250%
RI
29
RTW Investments
New York
$631K – – –
Bank of America
30
Bank of America
North Carolina
$618K +$252K +1,087 +50%
Renaissance Technologies
31
Renaissance Technologies
New York
$602K +$736K +3,180 New
N
32
Nuveen
North Carolina
$579K +$588K +2,541 +504%
CCM
33
Cinctive Capital Management
New York
$576K +$154K +666 +28%
Los Angeles Capital Management
34
Los Angeles Capital Management
California
$553K +$676K +2,921 New
CSS
35
Cubist Systematic Strategies
Connecticut
$513K +$500K +2,159 +393%
JF
36
Jump Financial
Illinois
$396K +$484K +2,093 New
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$333K +$135K +582 +49%
Morgan Stanley
38
Morgan Stanley
New York
$326K +$271K +1,172 +214%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$230K +$281K +1,213 New
PPA
40
Parametric Portfolio Associates
Washington
$199K +$122K +528 +101%
MIM
41
MetLife Investment Management
New Jersey
$193K +$236K +1,020 New
Citigroup
42
Citigroup
New York
$172K -$51.8K -224 -20%
Deutsche Bank
43
Deutsche Bank
Germany
$167K +$149K +643 +268%
TFS
44
TrustCore Financial Services
Tennessee
$160K +$77.1K +333 +65%
Two Sigma Investments
45
Two Sigma Investments
New York
$159K +$195K +841 New
AIG
46
American International Group
New York
$148K +$131K +567 +266%
Temasek Holdings
47
Temasek Holdings
Singapore
$135K – – –
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$127K +$106K +460 +216%
DCMIC
49
Decheng Capital Management III (Cayman)
Cayman Islands
$126K +$154K +667 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$124K +$151K +653 New
1
2
3 4

OMIC Hedge Fund Activity: Q1 2022 in Review

69 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q1 2022, worth a combined $259M — down 43% from $450M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OMIC positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 10 trimmed.

The largest buyer was UBS Group, adding an estimated $34.4M. The largest seller was Revelation Capital Management, cutting an estimated $23.1M.

  • 69 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q1 2022, up from 62 in Q4 2021.
  • Funds reported $259M of Singular Genomics Systems, Inc. Common Stock stock for Q1 2022, down 43% quarter-over-quarter.
  • 17 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of +7 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q1 2022 was UBS Group, an estimated $34.4M added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q1 2022 was Revelation Capital Management, an estimated $23.1M sold.

Based on aggregated 13F filings for Q1 2022.